Foresees a noticeable increase of customers, volume, and sales in 2024

STOCKHOLM – February 29, 2024 – Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, saw important pieces fall into place during the fourth quarter, the foremost being our attainment of accreditation as a medical laboratory. This paved the way for making Inify’s diagnostic service fully available to both private and public healthcare providers, resulting in a sales growth of 176% compared to the third quarter.

“I dare to claim that our operations are unique – in Sweden, and internationally. Our ambition is to stay at the forefront in terms of response times, quality and user-friendliness, for both customers and employees,” says CEO Fredrik Palm at Inify Laboratories. “I’ve said it before – we’re just getting started.”

In general, the healthcare sector struggles with high workload, long waiting times and inconsistent quality – challenges that certainly apply to prostate cancer diagnostics. Swedish guidelines state that a patient should receive their test results within 11 days from sampling; however, for many years, this has only been achieved with a small percentage of patients.

“All of Inify’s diagnoses have been delivered within our promised response time of 5 days, shortening the patient’s wait for a diagnosis by several weeks,” says Palm.

Inify’s first laboratory in Solna, near Karolinska Institute, has the capacity to provide diagnostic services for all prostate cancer cases in Sweden, as well as for healthcare providers abroad.

“The interaction between artificial intelligence, streamlined processes, dedicated employees, and enthusiastic customers has initiated a paradigm shift in prostate cancer diagnostics – to the benefit of many patients so far, and many more to come,” says Sales & Marketing Manager Maria Holmberg at Inify Laboratories.

”Success in our domestic market in Sweden will be followed by international establishments, where we continue to map the market, focusing on Europe. We foresee a noticeable increase in the number of customers, volume, and sales in 2024,” says CEO Fredrik Palm at Inify Laboratories.



For further information, please contact CEO, Fredrik Palm, , or visit 




About Inify Laboratories

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling; from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.



This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.


View attachment